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Abstract
Background: MCF2L2, ADIPOQ and SOX2 genes are located in chromosome 3q26-27, which is linked to diabetic
nephropathy (DN). ADIPOQ and SOX2 genetic polymorphisms are found to be associated with DN. In the present
study, we first investigated the association between MCF2L2 and DN, and then evaluated effects of these three
genes on the development of DN.
Methods: A total of 1177 type 1 diabetes patients with and without DN from the GoKinD study were genotyped
with TaqMan allelic discrimination. All subjects were of European descent.
Results: Leu359Ile T/G variant in the MCF2L2 gene was found to be associated with DN in female subjects (P =
0.017, OR = 0.701, 95%CI 0.524-0.938) but not in males. The GG genotype carriers among female patients with DN
had tendency decreased creatinine and cystatin levels compared to the carriers with either TT or TG genotypes.
This polymorphism MCF2L2-rs7639705 together with SNPs of ADIPOQ-rs266729 and SOX2-rs11915160 had
combined effects on decreased risk of DN in females (P = 0.001).
Conclusion: The present study provides evidence that MCF2L2, ADIPOQ and SOX2 genetic polymorphisms have
effects on the resistance of DN in female T1D patients, and suggests that the linkage with DN in chromosome 3q
may be explained by the cumulated genetic effects.
Background
T h eg l o b a li n c r e a s ei nd i a b e t e sp r e v a l e n c eh a sb e e n
accompanied by a rise in a number of patients with dia-
betic nephropathy (DN). This complication affects 30-
40% of the patients with type 1 (T1DM) and type 2 dia-
betes (T2DM), and has become the most common sin-
gle cause of end-stage renal disease (ESRD) [1,2].
Evidence has demonstrated that DN has genetic compo-
nents [3,4]. Therefore, identification of susceptibility or
resistance genes in DN will provide better knowledge of
pathomechanism and future therapies in this disease
[5,6].
With the approaches of genome wide scan and linkage
analyses, researchers have searched for the linkage to
DN along chromosomes. The linkage to DN in chromo-
some 3q has been evidenced repeatedly in many ethnic
groups, and indicated that there reside the susceptibility
and/or resistant genes for DN in this chromosomal arm
[7-13]. The adiponectin (ADIPOQ) gene is located
in chromosome 3q27. Vionnet et al. have analyzed
14 genes including the ADIPOQ gene selected from
chromosome 3q and found that a promoter polymorph-
ism rs17300539 (-11391A/G) in the ADIPOQ gene is
associated with DN in Danish T1DM patients [14]. We
have searched for the susceptibility and/or resistance
genes for DN in chromosome 3q with a positional can-
didate SNP genotyping approach. Our data indicate that
the ADIPOQ promoter polymorphism rs266729
(-11377C/G) is associated with DN in female T1DM
patients [15]. Another gene encoded by sex-determining
region Y-box 2 (SOX2) is located in chromosome
3q26.3. There is unique tag SNP rs11915160 in UTR-3’
in this intron-less gene. We have recently found that
this polymorphism is associated with DN in female sub-
jects with T1DM [16].
* Correspondence: harvest.gu@ki.se
Rolf Luft Center for Diabetes Research, Department of Molecular Medicine
and Surgery, Karolinska Institutet, Karolinska University Hospital, Solna,
Stockholm, Sweden
Zhang et al. BMC Medical Genetics 2010, 11:116
http://www.biomedcentral.com/1471-2350/11/116
© 2010 Zhang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.MCF.2 cell line derived transforming sequence-like 2
(MCF2L2) is a guanine-nucleotide exchange factor
(GEF) from Rho family. Evidence has demonstrated that
GEFs from Rho family are signaling molecules responsi-
ble for Rho protein activity. Over-activation of Rho
protein is a common component involved in the patho-
genesis of diabetes and several cardiovascular disorders,
including hypertension, coronary and cerebral vasos-
pasm and atherosclerosis [17,18]. Takeuchi et al. have
demonstrated that MCF2L2 genetic polymorphisms con-
fer the risk susceptibility to T2DM [19]. The MCF2L2
gene is located in chromosome 3q27, and resides
between locations of the ADIPOQ and SOX2 genes. In
the present study, we first genotyped genetic poly-
morphisms of the MCF2L2 gene and then performed
multiplex gene association analysis for MCF2L2, ADI-
POQ and SOX2 to evaluate their genetic effects on the
development of DN. The data may provide useful infor-
mation to better understand the linkage in chromosome
3q with DN.
Methods
Subjects
The subjects in Genetics of Kidney Diseases in Diabetes
(GoKinD) study were collected by the Juvenile Diabetes
Research Foundation in collaboration with the Joslin
Diabetes Centre, George Washington University, and
the United States Centres for Diabetes Control and Pre-
vention [20]. The GoKinD collection consists of both
singletons and trios, however, only singletons were
included in the present study. In this GoKinD cohort,
~8% of total subjects were Americans of Black, Asian,
Hispanic or Indian descents. In order to avoid the error
caused by the subjects from different races, this small
proportion of subjects were excluded from analyses.
Subsequently, a total of 599 (female 357/male 242)
T1DM patients without DN and 578 (265/313) T1DM
patients with DN were included, and all subjects were of
European descent. Presence of DN was defined either by
persistent proteinuria (urinary albumin excretion rate
>300 mg/24 h) in two out of three consecutive measure-
ments (at least one month apart), or ESRD (not due to
condition other than diabetes). Absence of DN was con-
sidered as persistent normal albuminuria (< 30 mg/24 h)
despite duration of T1DM for at least 15 years. Clinical
parameters of all subjects were collected by the GoKinD
study [20] and are represented in Table 1. Sample col-
lection of GoKinD study was approved by the local
ethics committees. Data and material transfer agreement
was completed prior to the study.
Marker selection and genotyping
Examined SNPs in the MCF2L2 gene were selected based
upon the information from International HapMap Project,
dbSNP databases http://www.ncbi.nlm.nih.gov/SNP/. Hap-
loview (ver4.1) was employed to visualize linkage disequili-
brium (LD) and haplotype block structures (r
2 > 0.8, LOD
threshold 3.0). Three SNPs i.e. rs684846, rs35069869 and
rs35368790 in the MCF2L2 gene are reported to be asso-
ciated with T2DM in a Japanese population [19]. Latest
information from dbSNP database indicates that SNP
rs684846 resides at 3’-flanking sequence but not within
the MCF2L2 gene region. Therefore, this polymorphism
was excluded from our study.
Rs7639705 is a non-synonymous SNP and causes
a m i n oa c i dc h a n g ef r o mL e ut oI l ea tt h ep o s i t i o n3 5 9
of MCF2L2 cDNA sequence. This polymorphism is a
tag marker for LD block 8 (8 kb) in the population of
European Caucasians (CEU, Haploview ver4.1). In the
Japanese study, however, SNP rs7639705 was not
included. In the present study, we validated this poly-
morphism with 32 subjects (64 chromosomes) randomly
selected from the GoKinD study cohort, and then
included it for genotyping analysis.
Table 1 Clinical material
T1DM without DN T1DM with DN
All Female Male All Female Male
N 599 357 242 578 265 313
Age (years) 40 ± 8 40 ± 9 40 ± 8 44 ± 6 44 ± 7 45 ± 6
Duration of diabetes (years) 26 ± 8 26 ± 8 26 ± 8 32 ± 8 32 ± 8 32 ± 8
HbA1c (%) 7.5 ± 1.1 7.5 ± 1.1 7.4 ± 1.1 7.4 ± 1.9 7.4 ± 2.1 7.4 ± 1.7
BMI (kg/m
2) 26.0 ± 4.4 25.7 ± 4.7 26.6 ± 3.7 25.7 ± 5.3 25.2 ± 5.7 26.2 ± 4.8
Creatinine (mg/dL) 0.9 ± 0.2 0.8 ± 0.1 1.0 ± 0.1 2.1 ± 1.9 1.9 ± 1.6 2.3 ± 2.0
Cystatin (mg/L) 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 2.2 ± 1.7 2.2 ± 1.6 2.4 ± 1.7
Cholesterol (mg/dL) 185.0 ± 31.3 188.7 ± 30.9 179.7 ± 31.2 186.3 ± 45.9 190.3 ± 47.3 183.1 ± 44.5
HDL (mg/dL) 59.1 ± 15.9 64.8 ± 15.5 51.0 ± 12.4 53.6 ± 17.3 59.3 ± 18.2 48.9 ± 15.0
Systolic BP (mm Hg) 118 ± 12 116 ± 12 122 ± 12 131 ± 19 130 ± 20 133 ± 18
Diastolic BP (mm Hg) 71 ± 8 70 ± 7 74 ± 8 74 ± 11 72 ± 11 75 ± 11
All data are means ± SD. T1DM = Type 1 diabetic patients, DN = diabetic nephropathy.
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Man allelic discrimination technique. SNP genotyping
assays that incorporate minor groove binding (MGB)
probes were purchased from Applied Biosystems (ABI
7 3 0 0 ,F o s t e rC i t y ,U S A ) .T h ea s s a yI Dn u m b e r sa n d
PCR protocol are available either on request or from
ABI database. For quality control, the subjects (cases
and controls) were distributed randomly on each PCR
plate. The negative (Universal-mixture blanks) controls
were included on each plate. Genotyping experiments in
20-25% of samples were performed in duplicate, and the
duplication accuracy was calculated to be 99%.
Gene-gene interaction analyses
Generalized multifactor dimensionality reduction
(GMDR) is a nonparametric and genetic model-free
alternative to linear or logistic regression program for
detection of gene-gene or gene-environmental interac-
tions [21,22]. We employed this program to investigate
gene-gene interactions concerning MCF2L2-rs7639705,
AdipoQ-rs266729 and Sox2-rs11915160. This program
provides a number of parameters including cross-valida-
tion consistency, testing balanced accuracy and empiri-
cal P-values to assess each selected interaction. The
GMDR analyses were performed separately in female
and male subjects. Logistic regression models were used
for confirmation of the data from GMDR analyses.
Statistical analyses
Hardy-Weinberg equilibrium (HWE) for individual loci
was assessed using the Pearson Chi-square (c
2)s t a t i s t i c .
A 2 × 2 contingency table was used for test of the
differences of allele frequencies between cases and con-
trols. The test with additive model and Cochran-Armi-
tage c
2 trend test for the combined equal additive
effects were used to identify differences in genotype dis-
tribution between cases and controls. Odds ratios (OR)
and 95% confidence intervals (CI) were calculated to
test the relative risk for association. Statistical powers
were calculated using software of PowerSampleSize (PS
version 2.1.31). The sample sizes of cases and controls
was sufficient to detect association with 80% power (5%
level) if allele frequencies 0.15 and 0.20. Tests for asso-
ciation between genotypes and quantitative traits were
performed by using ANOVA for normally distributed
traits, or alternatively Kruskal-Wallis analysis of ranks
for traits with non-normal distributions. Normal prob-
ability plots were created and parameter distributions
were transformed to natural logarithm when needed to
improve the skew-ness and for obtaining a normal dis-
tribution before performing statistical analysis of the
relevant phenotypes. Analyses were performed using
BioMed Data Program (BMDP ver1.12, Cork, Ireland)
and Statistica (ver7.1, StatSoft, Tulsa, OK, USA).
Results
Single gene analyses
We began with analysis of SNPs rs35069869, rs35368790
and rs7639705 in the MCF2L2 gene. Independent segre-
gation of alleles for these studied SNPs were tested in
the GoKinD population and they were kept in HWE
(P > 0.05). Genetic association analyses with Armitage’s
trend test, additive and dominant models were per-
formed and data are summarized in Table 2. In SNP
rs7639705 (T1165G, Leu359Ile), the G allele frequency
in the patients with DN compared to the patients with-
out DN was significantly lower in females (16.5% vs.
22.0%, P = 0.017, OR = 0.701) but not in males (19.7%
vs. 22.4%, P = 0.275). Comparison analysis of genotype
distribution indicated a significant association between
this polymorphism and DN among females (P = 0.018,
OR = 0.757). The same analyses in SNPs rs35069869
and rs35368790 between cases (T1DM with DN) and
controls (T1DM without DN) were done and no statisti-
cally significant association was found.
We further detected the association between pheno-
types and genotypes of SNP rs7639705 (T1165G,
Leu359Ile) in female T1DM patients with or without
DN. Figure 1 represents variations of the creatinine and
cystatin levels in female and male T1DM patients with
DN according to the genotypes of SNP rs7639705. In
females, the DN patients carrying TT and TG genotypes
had similar levels of creatinine (1.96 ± 1.55 and 1.95 ±
1.72 mg/mL) and cystatin (2.20 ± 1.66 and 2.21 ± 1.58
mg/L) in mean values, while the carriers with GG geno-
type had tendency decreased mean values of creatinine
and cystatin levels (1.44 ± 0.81 mg/mL; 1.73 ± 1.09 mg/
L) compared to the carriers with TT and TG genotypes.
But, the differences were not statistically significant in
both creatinine and cystatin levels (P = 0.074 and 0.058)
mainly due to the higher standard deviations. Among
male T1DM patients with DN, the GG genotype carriers
also showed tendency decreased but not significant
mean values of creatinine (1.68 ± 0.57 mg/mL vs. 2.29 ±
2.07 and 2.46 ± 2.05 mg/mL) and cystatin (1.85 ± 0.87
mg/L vs. 2.35 ± 1.77 and 2.52 ± 1.76 mg/L) levels com-
pared to the TT and TG genotype carriers. There was
no difference in creatinine and cystatin levels among
T1DM patients without DN in both females and males
who carry three different genotypes (data not shown).
Multi-gene analyses
We have recently genotyped SNPs rs266729 and
rs11915160, respectively, in the ADIPOQ and SOX2
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cate that these two polymorphisms have an interactive
association effect with DN in female T1DM patients
[15,16]. In the present study, we employed the GMDR
analyses to assess the impact of combinations with the
model of MCF2L2 (rs7639705)-SOX2 (rs11915160)-ADI-
POQ (rs266729) in 622 female subjects. Table 3 presents
the gene-gene interaction and impact of MCF2L2, SOX2
and ADIPOQ genetic polymorphisms in DN among
female T1DM patients from GoKinD population. Data
were obtained from GMDR analyses without covariate
adjustment. There was a significant three-gene model
(empirical P-value = 0.001). The model had the cross-
validation consistency of 10/10 and testing accuracy of
56.2%. The significance was confirmed by a logistic
regression model (P < 0.001). The analyses with two-
gene model i.e. MCF2L2 together with either ADIPOQ
or SOX2 genetic polymorphisms were also performed,
and no significant interaction of MCF2L2-ADIPOQ or
MCF2L2-SOX2 (P = 0.377, 0.623). The GMDR analysis
with the same models studied in females was also per-
formed in male subjects and no significant data were
observed.
Discussion
We have used a positional candidate gene research
approach to search for the susceptibility or resistance
genes in DN. Three candidates including MCF2L2, ADI-
POQ and SOX2 in chromosome 3q26-27 are selected
for the genotyping analyses. The MCF2L2 gene has the
distances of 1,463 kb and 3,415 kb, respectively, to the
location of SOX2 and ADIPOQ. In the present study, we
found that SNP rs7639705 (T1165G Leu359Ile) in the
MCF2L2 gene is significantly associated with decreased
risk of DN in female T1DM patients in the GoKinD
population. The patients carrying GG genotype have
tendency decreased creatinine and cystatin levels com-
pared to the TT and TG carriers. Serum creatinine and
cystatin levels are useful for prediction of the impact on
renal function measurement and prognostic stages of
DN. Therefore, the data suggest that MCF2L2 may have
resistant genetic effects on DN.
Takeuchi et al. have reported that two intronic poly-
morphisms i.e. rs35069869 and rs35368790 in the
MCF2L2 gene are associated with T2DM in a Japanese
population [19], but the Leu359Ile polymorphism is not
included in their study. Interestingly, FARP2 encoded
for FERM, pleckstrin domain protein 2 is another Rho
GEF in the same family. Savage et al. have demonstrated
that rs757978 in the FARP2 gene is associated with
ESRD in T1DM, and the G allele frequency of this poly-
morphism in T1DM patients with ESRD was lower than
the control subjects (0.090 vs 0.118, P = 0.008) [23].
Rs757978 is a non-synonymous polymorphism causing
amino acid change from Thr to Ile at the code 260 of
FARP2 cDNA. This is similar to what we have found in
the MCF2L2 gene. Furthermore, the recent biological
studies have indicated that GEFs of Rho family may reg-
ulate GTPase Cdc42 activity and subsequently contri-
bute to the processes of macro-and/or micro-vascular
Table 2 Association between the MCF2L2 genetic polymorphisms and diabetic nephropathy
SNP ID
Hit Orientation
Group Genotype Frequency Allele Frequency Association Significance
P-value/Odds ratio (95% CI)
rs35069869 Women AA AG GG A G
A/G T1D without DN 174 (0.489) 153 (0.430) 29 (0.081) 0.704 0.211
T1D with DN 135 (0.509) 109 (0.411) 21 (0.079) 0.715 0.285 0.661
a
Men
T1D without DN 125 (0.519) 101 (0.419) 15 (0.062) 0.728 0.272
T1D with DN 150 (0.479) 137 (0.438) 26 (0.083) 0.698 0.302 0.273
a
rs35368790 Women GG GC CC G C
G/C T1D without DN 168 (0.471) 151 (0.423) 38 (0.106) 0.682 0.318
T1D with DN 134 (0.511) 107 (0.408) 33 (0.105) 0.716 0.284 0.204
a
Men
T1D without DN 107 (0.442) 110 (0.455) 25 (0.103) 0.669 0.331
T1D with DN 146 (0.466) 134 (0.428) 33 (0.105) 0.681 0.319 0.696
a
rs7639705 Women TT TG GG T G
T1165G T1D without DN 213 (0.603) 125 (0.354) 15 (0.043) 0.780 0.220
Leu359Ile T1D with DN 188 (0.712) 65 (0.246) 11 (0.042) 0.835 0.165 0.017/0.701 (0.524-0.938)
a
0.018/0.757
b
Men
T1D without DN 157 (0.651) 73 (0.303) 11 (0.046) 0.803 0.197
T1D with DN 183 (0.590) 115 (0.371) 12 (0.039) 0.776 0.224 0.275
a
T1D = type 1 diabetes, DN = diabetic nephropathy. Association significances = a. test for allele frequency difference (additive model), and b. for Armitage’s trend.
Zhang et al. BMC Medical Genetics 2010, 11:116
http://www.biomedcentral.com/1471-2350/11/116
Page 4 of 7diseases [24,25]. Therefore, we have a hypothesis that
GEFs of Rho family may play an important role in dia-
betic micro-vascular complications. At the present stage,
information of MCF2L2 and FARP2 in patho-physiology
is very limited. Further investigation is necessary to
investigate the direct effect of the Rho family GEFs,
particularly MCF2L2 and FARP2, on the development of
DN or indirect influence via variation of GTPase
activity.
Several genetic linkage analyses have predicted that a
chromosomal region on 3q is linked to diabetes and DN
[7-13]. Therefore, researchers have searched for the
Figure 1 Variation of creatinine and cystatin levels among female and male type 1 diabetes patients with diabetic nephropathy
according to the genotypes of Leu359Ile variant in the MCF2L2 gene. Untransformed mean values (± SD) for creatinine and cystatin levels
in female and male type 1 diabetes patients with DN are shown. The patients with DN carrying GG genotype had tendency decreased levels of
creatinine and cystatin compared the carriers with TT and TG genotypes. But, the differences were not statistically significant mainly due to the
higher standard deviations.
Table 3 MCF2L2, Sox2 and AdipoQ gene-gene interaction and impact on diabetic nephropathy in female type 1
diabetic patients
Best combination Cross-validation consistency Testing accuracy (%) P-value
MCF2L2 (rs7639705) - Sox2 (rs11915160) - AdipoQ (rs266729) 10/10 0.562 0.001
MCF2L2 (rs7639705) - Sox2 (rs11915160) 10/10 0.513 0.623
MCF2L2 (rs7639705) - AdipoQ (rs266729) 10/10 0.545 0.377
P-values were based upon 1000 permutations.
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region of this chromosomal arm. He et al. have recently
genotyped 3072 tag SNPs) spanning a 28 Mb region
around chromosome 3q22 and found that rs1866813 is
associated with DN. However, this is an intergenic poly-
morphism and no gene conferring the susceptibility risk
to DN has been identified [26]. Vionnet et al. have
selected and studied 14 candidate genes including
AGTR1, PTX3, IL12A, SLC2A2, TNFSF10, ECE2, THPO,
E H H A D H ,H R G ,K N G 1 ,A d i p o Q ,S S T ,P P P 1 R 2and
APOD from chromosome 3q24-29 and found that the
AdipoQ promoter polymorphism rs17300539 is asso-
ciated with DN in T1DM patients in Danish, but not in
French and Finnish populations [14]. We have studied
the candidate genes including TRPC1 (3q22-24), MME
(3q25), SOX2 (3q26.3), MCF2L2 (3q27) and ADIPOQ
(3q27). We have found that the AdipoQ promoter poly-
morphism-11377C/G is associated with DN in female
subjects from the GoKinD population [15]. This poly-
morphism alters the sequence in one of transcription
factor SP1 binding sites and causes reduction of ADI-
POQ promoter activity [27,28]. Moreover, the investiga-
tors in the field of stem cell research have amply
demonstrated that four transcription factors, including
Oct3/4, Sox2, Klf4 and c-Myc, play an important role in
induction of pluripotent stem cells from somatic cells
([29-32]. We have recently performed a genetic study of
the Sox2gene in the same GoKinD cohort as studied in
the MCF2L2 and AdipoQ genes, and found that Sox2
genetic polymorphism is associated with DN in female
T1DM subjects [16]. The MCF2L2 gene has the dis-
tances of 146 kb and 341 kb, respectively, to the loca-
tion of Sox2 and AdipoQ. In order to evaluate whether
MCF2L2 has gene-gene interaction with ADIPOQ and
Sox2 in term of association with DN, we have performed
gene-gene interaction analysis. The results suggest that
MCF2L2 has combined genetic effects with both ADI-
POQ and Sox2 on DN among female subjects but not
with either ADIPOQ or Sox2 alone. The linkage of chro-
mosome 3q to DN is most likely determined by the
multiplex loci, including these three genes.
Evidence has indicated that gender is an important risk
factor for the development and progression of DN. This
disease appears less frequently in females than in males
with a ratio of approximately 1:1.3 [33]. Previously, Pet-
tersson-Fernholm et al. have demonstrated that the AT2
genetic polymorphisms confer risk susceptibility to the
development of DN in male but not female T1DM sub-
jects of Finnish population [34]. In the present study, we
have demonstrated that MCF2L2, AdipoQ and Sox2
genetic polymorphisms have protective effects on DN in
female T1DM patients. The genetic association of
MCF2L2, AdipoQ and Sox2 genetic polymorphisms with
DN in male T1DM patients is not observed. The pattern
of tendency decreased creatinine and cystatin levels in
DN patients carrying GG genotype compared to the TT
and TG carriers is seen in both females and males.
Therefore, the genotypic and phenotypic differences in
gender should be taken into our consideration in genetic
and functional analyses of DN.
Conclusions
The present study provides the first evidence that the
MCF2L2 Leu359Ile polymorphism is associated with
decreased risk of DN in female T1DM patients.
MCF2L2 together with ADIPOQ and Sox2 genetic poly-
morphisms have combined genetic effects on DN in
females, which reveals that the linkage of chromosome
3q to DN may be explained by the accumulated effects
of multi-genes.
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